美国毒物中心报告的加巴喷丁与巴氯芬暴露趋势
该研究为美国毒物中心国家毒物数据系统的回顾性分析,纳入2013—2017年加巴喷丁暴露及2014—2017年巴氯芬暴露的18岁及以上患者。五年间加巴喷丁暴露共74175例,全部暴露增加72.3%,孤立暴露增加67.1%,孤立滥用/误用暴露增加119.9%;四年间巴氯芬暴露共15397例,全部暴露增加36.2%,孤立暴露增加35.0%,孤立滥用/误用暴露增加31.7%。两药常见合并摄入镇静剂和阿片类;孤立加巴喷丁暴露需住院者占16.7%,孤立巴氯芬暴露需住院者占52.1%。作者结论认为两药滥用、毒性、自杀未遂使用及相关医疗利用显著增加,处方时应仔细考虑并做风险获益分析。
要点
- 2013—2017年加巴喷丁暴露共74175例,全部暴露增加72.3%,孤立滥用/误用暴露增加119.9%。
- 2014—2017年巴氯芬暴露共15397例,全部暴露增加36.2%,孤立滥用/误用暴露增加31.7%。
- 孤立加巴喷丁暴露需住院者占16.7%,孤立巴氯芬暴露需住院者占52.1%。
- 加巴喷丁与巴氯芬均常见合并摄入镇静剂和阿片类。
- 孤立加巴喷丁暴露的自杀未遂在五年间增加80.5%,孤立巴氯芬暴露在四年间增加43%。
适用人群与场景
- 美国毒物中心报告的18岁及以上加巴喷丁暴露(2013—2017年)和巴氯芬暴露(2014—2017年)患者。
研究设计与关键结果
- 研究类型为美国毒物中心国家毒物数据系统的回顾性分析,纳入18岁及以上加巴喷丁暴露74175例(2013—2017年)和巴氯芬暴露15397例(2014—2017年)。
- 加巴喷丁全部暴露增加72.3%,孤立暴露增加67.1%,孤立滥用/误用暴露增加119.9%。
- 巴氯芬全部暴露增加36.2%,孤立暴露增加35.0%,孤立滥用/误用暴露增加31.7%。
- 两药均常见合并摄入镇静剂和阿片类。
- 孤立加巴喷丁暴露需住院者占16.7%,孤立巴氯芬暴露需住院者占52.1%。
- 孤立加巴喷丁暴露的自杀未遂在五年间增加80.5%,孤立巴氯芬暴露在四年间增加43%。
- 所有州均见加巴喷丁暴露增加,大多数州见巴氯芬暴露、加巴喷丁滥用/误用及巴氯芬滥用/误用增加。
证据类型、等级与局限
- 证据类型为基于美国毒物中心国家毒物数据系统的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,自2013年以来美国成人中加巴喷丁与巴氯芬的滥用、毒性、自杀未遂使用及相关医疗利用显著增加。
- 作者认为,处方这些药物时应仔细考虑并进行风险获益分析。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Context: Prescriptions for nonopioid pharmacological therapies such as gabapentin and baclofen have been increasing. While gabapentin and baclofen are less likely than opioids to result in fatal overdose, they are each associated with dependence, misuse and adverse effects.Objective: The objective of this study is to evaluate and describe trends in adult exposures to gabapentin and baclofen reported to U.S. Poison Centers.Methods: This was a retrospective review of data collected by U.S. Poison Centers and entered in the National Poison Data System. We identified all cases of exposures to gabapentin (2013-2017) and baclofen (2014-2017) in patients aged 18 years and over. We then analyzed demographics, common co-ingestions, medical outcomes, and geographic distribution.Results: During the five-year period (2013-2017), there were 74,175 gabapentin exposures. All gabapentin exposures increased by 72.3%; isolated exposures increased by 67.1%; and isolated abuse/misuse exposures increased by 119.9%. During the four-year period (2014-2017), there were 15,397 baclofen exposures. All baclofen exposures increased by 36.2%; isolated exposures increased by 35.0%; and isolated abuse/misuse exposures increased by 31.7%. Co-ingestions of sedatives and opioids were common for both medications. Admissions to a health care facility were required in 16.7% of isolated gabapentin exposures, and 52.1% of isolated baclofen exposures. Intentional suspected suicide attempts with isolated gabapentin exposures increased by 80.5% over a five-year period; and increased by 43% for isolated baclofen exposures over a four-year period. All states saw increases in gabapentin exposures and most states saw increases in baclofen exposures, gabapentin misuse/abuse, and baclofen misuse/abuse.Conclusion: Gabapentin and baclofen misuse, toxicity, use in suicide attempts, and associated healthcare utilization among adults in the United States have significantly increased since 2013. Careful consideration and risk-benefit analysis should be employed when prescribing these medications.
参考来源
- Reynolds K, Kaufman R, Korenoski A, et al. Trends in gabapentin and baclofen exposures reported to U.S. poison centers. Clin Toxicol (Phila). 2019. PMID: 31786961. doi:10.1080/15563650.2019.1687902
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。